TELA BIO, INC. (TELA): Price and Financial Metrics
TELA Price/Volume Stats
| Current price | $5.58 | 52-week high | $13.18 |
| Prev. close | $5.45 | 52-week low | $4.23 |
| Day low | $5.34 | Volume | 96,100 |
| Day high | $5.65 | Avg. volume | 100,104 |
| 50-day MA | $5.88 | Dividend yield | N/A |
| 200-day MA | $8.91 | Market Cap | 136.65M |
TELA Stock Price Chart Interactive Chart >
TELA POWR Grades
- Sentiment is the dimension where TELA ranks best; there it ranks ahead of 70.01% of US stocks.
- The strongest trend for TELA is in Growth, which has been heading down over the past 177 days.
- TELA's current lowest rank is in the Quality metric (where it is better than 4.73% of US stocks).
TELA Stock Summary
- With a one year PEG ratio of 283.36, TELA BIO INC is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 89.08% of US stocks.
- Revenue growth over the past 12 months for TELA BIO INC comes in at 39.05%, a number that bests 88.06% of the US stocks we're tracking.
- TELA BIO INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -33.53%, greater than the shareholder yield of merely 11.6% of stocks in our set.
- Stocks that are quantitatively similar to TELA, based on their financial statements, market capitalization, and price volatility, are STIM, PWFL, DUOT, MYO, and BSQR.
- TELA's SEC filings can be seen here. And to visit TELA BIO INC's official web site, go to www.telabio.com.
TELA Valuation Summary
- TELA's price/sales ratio is 2.2; this is 18.92% higher than that of the median Healthcare stock.
- Over the past 49 months, TELA's EV/EBIT ratio has gone up 5.4.
Below are key valuation metrics over time for TELA.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| TELA | 2023-11-20 | 2.2 | 3.9 | -2.7 | -2.6 |
| TELA | 2023-11-17 | 2.2 | 3.8 | -2.6 | -2.5 |
| TELA | 2023-11-16 | 2.2 | 3.8 | -2.7 | -2.5 |
| TELA | 2023-11-15 | 2.2 | 3.8 | -2.7 | -2.6 |
| TELA | 2023-11-14 | 2.1 | 3.6 | -2.5 | -2.4 |
| TELA | 2023-11-13 | 2.1 | 3.6 | -2.5 | -2.4 |
TELA's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- TELA has a Quality Grade of C, ranking ahead of 27.58% of graded US stocks.
- TELA's asset turnover comes in at 0.295 -- ranking 132nd of 183 Medical Equipment stocks.
- 500 - Internal server error
The table below shows TELA's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.295 | 0.635 | -0.825 |
| 2021-03-31 | 0.230 | 0.614 | -0.754 |
| 2020-12-31 | 0.217 | 0.617 | -0.700 |
| 2020-09-30 | 0.220 | 0.605 | -0.624 |
| 2020-06-30 | 0.260 | 0.613 | -0.546 |
| 2019-12-31 | 0.325 | 0.600 | -0.536 |
TELA Price Target
For more insight on analysts targets of TELA, see our TELA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $20.00 | Average Broker Recommendation | 1.25 (Strong Buy) |
TELA BIO, INC. (TELA) Company Bio
TELA Bio, Inc. is a commercial stage medical technology company. It focuses on designing, developing and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company offers a portfolio of advanced reinforced tissue matrices that improve clinical outcomes and reduce overall costs of care in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery. TELA Bio was founded by Antony Koblish and Maarten Persenaire on April 17, 2012 and is headquartered in Malvern, PA.
Latest TELA News From Around the Web
Below are the latest news stories about TELA BIO INC that investors may wish to consider to help them evaluate TELA as an investment opportunity.
TELA Bio to Participate in Piper Sandler’s 35th Annual Healthcare ConferenceMALVERN, Pa., Nov. 16, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today announced that the Company will participate in Piper Sandler’s 35th Annual Healthcare Conference. TELA’s management is scheduled to present at Piper Sandler’s 35th Annual Healthcare Confere |
TELA Bio, Inc. (NASDAQ:TELA) Q3 2023 Earnings Call TranscriptTELA Bio, Inc. (NASDAQ:TELA) Q3 2023 Earnings Call Transcript November 12, 2023 Operator: Good day and thank you for standing by, and welcome to the TELA Bio Third Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions] Please be advised that today’s conference call is being recorded. I […] |
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)MALVERN, Pa., Nov. 10, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 40,700 shares of its common stock |
TELA Bio Reports Third Quarter 2023 Financial ResultsMALVERN, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today reported financial results for the third quarter ended September 30, 2023. Recent Highlights Revenue of $15.1 million in the third quarter, representing growth of 35% over the third quarter o |
TELA Bio to Announce Third Quarter 2023 Financial ResultsMALVERN, Pa., Oct. 26, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today announced that the Company will report third quarter 2023 financial results on Thursday, November 9, 2023. TELA Bio’s management will host a conference call and webcast at 4:30 |
TELA Price Returns
| 1-mo | -2.45% |
| 3-mo | -37.65% |
| 6-mo | -49.55% |
| 1-year | -41.75% |
| 3-year | -65.89% |
| 5-year | N/A |
| YTD | -51.48% |
| 2022 | -10.16% |
| 2021 | -14.89% |
| 2020 | 16.14% |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...